�鶹Ů��

The Supreme Court’s mifepristone decision on June 13 put a stop to one challenge to the drug used in more than half of all abortions in the United States. But antiabortion groups are already preparing their next line of attack. (Mary Ziegler, 6/24)

I have spent my career studying infectious diseases that fall under the heading of neglected tropical diseases. Now I have a neglected and incurable (for now and for me) disease — long COVID. (Rachel Hall-Clifford, 6/24)

Roughly 25 million Americans were uninsured in 2023, down from 27.6 million in 2022 and 33.2 million in 2019, according to a National Center for Health Statistics report. Unfortunately, an estimated 5 million Texans, or 16.6%, are uninsured, a percentage more than twice the national average of 7.6% in 2023. That ranks Texas dead last among the states by a large margin. (6/25)

Many people have interpreted as a setback the “no” vote by an advisory committee to the Food and Drug Administration on Lykos Therapeutics’ new drug application for MDMA-assisted psychotherapy for post-traumatic stress disorder. We believe it is an opportunity to build upon Lykos’ success and rally support for better-funded, well-controlled clinical trials to determine the safety and efficacy of a promising PTSD treatment. (Andrew D. Forsyth, Mallory O. Johnson and Jae M. Sevelius, 6/25)

Drug discovery has quickly become the most enticing place to apply artificial intelligence. Billions of dollars are being invested in AI-driven “techbios.” In an industry where nothing changes overnight, even large biopharma companies are touting AI as key to how they’re transforming their discovery engines. (Ashu Singhal and Sajith Wickramasekara, 6/25)